Skip to main content
Clinical Trials/NCT05347667
NCT05347667
Completed
Not Applicable

Influence of Menstrual Cycle Phase and Oral Contraceptive Pill (OCP) Use on the Muscle Protein Synthetic Response to Exercise in Young, Healthy Women

McMaster University1 site in 1 country24 target enrollmentMay 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Menstrual Cycle
Sponsor
McMaster University
Enrollment
24
Locations
1
Primary Endpoint
Change in Rates of Muscle Protein Synthesis
Status
Completed
Last Updated
last year

Overview

Brief Summary

Skeletal muscle size and function is regulated by various factors, including hormones. While we understand the role of male sex hormones (testosterone), we aren't sure how female sex hormones (estrogen and progesterone) influence muscle mass and strength. Female physiology is unique in that hormones fluctuate throughout the menstrual cycle. In the first phase (follicular phase) following menstruation, estrogen levels are high while progesterone levels are low. In the second phase (luteal phase), progesterone levels are high. Females are often excluded from studies because researchers are concerned that the menstrual cycle might affect the results. The purpose of this study is to investigate the response to resistance exercise in each phase of the menstrual cycle.

Registry
clinicaltrials.gov
Start Date
May 1, 2022
End Date
April 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stuart Phillips

Professor

McMaster University

Eligibility Criteria

Inclusion Criteria

  • Healthy females, between the ages of 18 and 30 y with a regular menstrual cycle
  • Body Mass Index between 18.5 and 30.0 kg/m2
  • Able and willing to provide informed consent

Exclusion Criteria

  • A history of neuromuscular disorders or muscle/bone wasting diseases
  • Any acute or chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin-dependent or insulin-independent diabetes, or the presence of any other metabolic disease - all of which will be determined via a medical history screening questionnaire
  • The use of any medications known to affect protein metabolism (glucocorticoids, non-steroidal anti-inflammatory medication, or prescription strength acne medication, etc.)
  • A (family) history of thrombosis
  • The use of anticoagulant medications
  • Consumption of tobacco-containing products
  • Excessive alcohol consumption (\>21 units/wk)
  • History of bleeding diathesis, platelet or coagulation disorders
  • Currently pregnant
  • Irregular menstrual cycle as defined in the study protocol

Outcomes

Primary Outcomes

Change in Rates of Muscle Protein Synthesis

Time Frame: 6 days

The investigators will use deuterated water and skeletal muscle biopsies to calculate the synthesis of skeletal muscle proteins.

Secondary Outcomes

  • Whole-body proteolysis(6 days)

Study Sites (1)

Loading locations...

Similar Trials